Allspring Global Investments Holdings LLC Sells 10,619 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Allspring Global Investments Holdings LLC cut its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 17.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 51,791 shares of the company’s stock after selling 10,619 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Teva Pharmaceutical Industries were worth $933,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. New Covenant Trust Company N.A. purchased a new stake in Teva Pharmaceutical Industries during the first quarter worth about $28,000. EntryPoint Capital LLC purchased a new position in Teva Pharmaceutical Industries in the first quarter valued at approximately $30,000. UMB Bank n.a. lifted its position in shares of Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after buying an additional 2,067 shares during the last quarter. Beach Investment Counsel Inc. PA purchased a new stake in Teva Pharmaceutical Industries during the second quarter valued at about $48,000. Finally, Byrne Asset Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at approximately $52,000. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Trading Down 0.8 %

Shares of NYSE:TEVA opened at $18.45 on Friday. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. The stock has a market capitalization of $20.90 billion, a price-to-earnings ratio of -45.00, a PEG ratio of 1.29 and a beta of 0.88. The stock’s 50-day simple moving average is $18.03 and its two-hundred day simple moving average is $16.88. Teva Pharmaceutical Industries Limited has a 52-week low of $8.42 and a 52-week high of $19.08.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The business had revenue of $4.16 billion during the quarter, compared to analyst estimates of $3.99 billion. Analysts expect that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Wednesday, July 10th. UBS Group upped their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Barclays upped their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.